Axial Length and Central Corneal Thickness in Benign Intracranial Hypertension

Benign Intracranial Hypertension Clinical Trial

Official title:

The Potential Value of Axial Length and Central Corneal Thickness in the Assessment for Risk of Permanent Optic Nerve Damage and Visual Field Loss in Benign Intracranial Hypertension

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02541994
• Other study ID #: 2015.002.A
• Status: Terminated
• Phase: N/A
• Start date: September 2015
• Est. completion date: September 2017

Study information

• Verified date: February 2024
• Source: Ochsner Health System
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients in for treatment of benign intracranial hypertension will undergo two tests that are not routinely performed for these patients: central corneal thickness and axial length of the eye. The data obtained from these measurements will be assessed to see if the correlate with aspects of vision loss including visual acuity, visual field status, optical coherence tomography (OCT) results, and fundus photographs.

Description:

Patients with benign intracranial hypertension would be identified at diagnosis from the general ophthalmic and neurologic patient population in the Ochsner Health System. All would have a baseline eye examination with visual field and optical coherence tomography (OCT) testing, a standard step in managing any patient with this condition. Two measurements would be taken at minimal risk to the patient that they would not normally have done at the baseline exam: central corneal thickness and axial length. These procedures are routinely done on patients with glaucoma, corneal disease, and cataracts without a significant risk of injury. The theoretical risks with central corneal thickness and axial length measurements by A-scan ultrasonography are related to the small risk for transmission of infection or corneal abrasion due to a probe touching the cornea. These tests would be performed at no charge to the patient and would not significantly increase the time of the ocular examination. Patients would have neuro-imaging studies and lumbar puncture to confirm the diagnosis of benign intracranial hypertension as standard parts of the work up for the condition independent of the research study. The authors will statistically analyze the standard measures of visual field function and health of the nerve fiber layer by OCT to see if any or all of the proposed risk factors correlates with deterioration of visual function. Data would continue to be collected at follow up visits related to visual fields and OCT as would normally be performed on standard visits for this condition. The measurements of central corneal thickness and axial length would be performed solely at the time of enrollment in the study since these measurements do not change over time.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: September 2017
• Est. primary completion date: November 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must have benign intracranial hypertension.

Exclusion Criteria:

• None

Related Conditions & MeSH terms

• Benign Intracranial Hypertension
• Hypertension
• Intracranial Hypertension
• Pseudotumor Cerebri

Intervention

Device:
• Pachette3
Central corneal thickness will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.
• Lenstar-Think
Axial length will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Ochsner Health System

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Axial Length	The length of the eye will be measured with ultrasound.	Single measurement during ultrasound procedure on the day of enrollment in the study on average of 5 minutes.
Secondary	Central Corneal Thickness	The thickness of the cornea will be measured with ultrasound.	Single measurement during ultrasound procedure at the time of enrollment in the study on average of 5 minutes.